

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 27, 2002

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS

Laboratory Corporation of America -Registered Trademark-Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced the creation of an exclusive, long-term strategic partnership to commercialize PreGen-Plus-Trademark-, EXACT Sciences' proprietary, non-invasive technology for the early detection of colorectal cancer in the average-risk population. As part of the agreement, in addition to certain royalty fees, LabCorp could pay EXACT Sciences as much as \$75 million in upfront, milestone and performance-based payments for a five-year exclusive license, followed by a non-exclusive license for the life of the patents. The introduction of Pre-Gen Plus, expected in the first half of 2003, will mark the broadest commercial application of discoveries made about the human genome to address a major healthcare problem such as colorectal cancer-the most deadly cancer among non-smokers in the United States. There is no other DNA-based test currently available for the early detection of cancer in an average-risk population.

It is estimated that this year approximately 150,000 Americans will be diagnosed with colorectal cancer and approximately 57,000 Americans will die from the disease. The American Cancer Society recommends that the 80 million Americans who are over the age of 50 be screened regularly for colorectal cancer, which, if detected at an early stage, has a cure rate of more than 90 percent. A majority of people, however, avoid screening because of the inconvenience and discomfort associated with certain currently available screening methods, with the result that most colorectal cancer cases are detected at a later stage when the cure rate is less than 50 percent.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS

(c) Exhibit

20 Press release of the Company dated June 27, 2002.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By:/s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President
and Secretary

Date: June 27, 2002

FOR IMMEDIATE RELEASE
For further information:
For EXACT Sciences:
Media:
Amy Turner
Fleishman-Hillard
P:(617)267-8223
E:turnera@fleishman.com

Investor Relations and
Corporate Communications:
Amy Hedison
EXACT Sciences
P:(978)897-2800,ext,252
E:ahedison@exactsciences.com

For LabCorp:
Pam Sherry
LabCorp
P:(336)436-4855
E:sherry@labcorp.com

EXACT SCIENCES AND LABCORP -REGISTERED
TRADEMARK- TO OFFER PREGEN-PLUS -
TRADEMARK- CHANGING THE HEALTH CARE
LANDSCAPE WITH NON-INVASIVE, GENOMICS-
BASED COLORECTAL CANCER TECHNOLOGY

Exclusive Licensing Agreement to Make PreGen-Plus
Available to a Potential Market of 80 Million Americans; Will Mark the
First DNA-based Screening Method for Cancer in an Average-Risk Population

Maynard, Mass., and Burlington, N.C., - June 27, 2002 - EXACT
Sciences Corporation (NASDAQ: EXAS) and Laboratory Corporation
of America -Registered Trademark-) Holdings (NYSE:LH) (LabCorp-
Registered Trademark-) today announced the creation of an exclusive,
long-term strategic partnership to commercialize PreGen-Plus -
Trademark-, EXACT Sciences' proprietary, non-invasive technology for
the early detection of colorectal cancer in the average-risk population.
As part of the agreement, in addition to certain royalty fees, LabCorp
could pay EXACT Sciences as much as \$75 million in upfront,
milestone and performance-based payments for a five-year exclusive
license, followed by a non-exclusive license for the life of the patents.
The introduction of PreGen-Plus, expected in the first half of 2003, will
mark the broadest commercial application of discoveries made about
the human genome to address a major healthcare problem such as
colorectal cancer - the most deadly cancer among non-smokers in the
United States. There is no other DNA-based test currently available
for the early detection of cancer in an average-risk population.

It is estimated that this year approximately 150,000 Americans will be
diagnosed with colorectal cancer and approximately 57,000 Americans
will die from the disease. The American Cancer Society recommends
that the 80 million Americans who are over the age of 50 be screened
regularly for colorectal cancer, which, if detected at an early stage, has
a cure rate of more than 90 percent. A majority of people, however,
avoid screening because of the inconvenience and discomfort
associated with certain currently available screening methods, with the
result that most colorectal cancer cases are detected at a later stage
when the cure rate is less than 50 percent.

LabCorp's first payment to EXACT Sciences of \$15 million was made
upon the signing of the agreement, and the second payment of \$15
million will be made upon the commercial launch of PreGen-Plus,
which is expected in the first half of 2003. Of the remaining \$45
million, milestone payments from LabCorp totaling \$30 million will be
based upon EXACT Sciences deliverables related to scientific
acceptance, reimbursement approval and technology improvements
and \$15 million will be based upon the achievement of significant
revenue thresholds. In addition to these payments, EXACT Sciences
will receive a royalty fee for each PreGen-Plus test performed by
LabCorp. In conjunction with the partnership, EXACT Sciences has
issued to LabCorp a warrant to purchase 1,000,000 shares of EXACT
Sciences common stock, exercisable over the next three years at an
exercise price of \$16.09.

"The proprietary technology underlying the PreGen-Plus assay
creates a very accurate and patient-friendly test, and therefore
represents a significant step forward in the early detection of colorectal
cancer in the average-risk population," said Thomas P. Mac Mahon,
LabCorp's Chairman and CEO. "We believe PreGen-Plus could be the
most important molecular test identified to date for the millions of
Americans who are candidates for colorectal cancer screening
annually."

Mr. Mac Mahon continued, "Our agreement with EXACT Sciences is another example of LabCorp's pioneering leadership position in molecular diagnostics and our ability to recognize the potential of DNA-based testing. EXACT Sciences brings that same visionary approach in applying the discoveries of the human genome to create novel DNA-based assays that address major healthcare problems. We are excited about combining our skills with EXACT Sciences' to improve diagnostic testing for cancer."

"As the first DNA-based test that will be used for population-based cancer screening, PreGen-Plus truly changes the molecular diagnostics landscape," said Don Hardison, EXACT Sciences' President and CEO. "The scope of this partnership - both in economic terms and, more importantly, in terms of lives saved - highlights the power of applied genomics. As a leader in bringing the knowledge of the human genome to reality, EXACT Sciences is delighted to be working with LabCorp, given its unique scale, expertise and infrastructure, to make this important test widely available. We are confident that the fruits of our strategic relationship will result in greater numbers of Americans being screened for the disease and the prevention of many deaths from colorectal cancer."

PreGen-Plus works by isolating human DNA that is shed in the colon everyday and carried out of the body in stool, and analyzing that DNA for mutations associated with colorectal cancer. PreGen-Plus is a completely non-invasive, patient-friendly technology that requires no dietary modification or bowel preparation. The simple process involves collecting a single stool sample in the privacy of a patient's own home, and shipping the sample in a supplied container and packaging materials to LabCorp's facilities for analysis. Following the analysis, LabCorp will send the test results to the patient's physician for use in connection with future monitoring and treatment.

Informational Conference Call

EXACT Sciences, with LabCorp participating, will host a conference call to discuss this partnership at 8:30 a.m. ET on Thursday, June 27, 2002. A live Webcast of the conference call, and an archived version following the completion of the call, will be available at www.exactsciences.com, www.labcorp.com and www.companyboardroom.com. The conference call and Webcast are open to all interested parties. Information for the call follows: Call in number for listen-only participants: 212-676-5273 A telephone replay of the conference call will be available beginning at 11:00 a.m. on June 27th through July 11th. Information for the replay is as follows:

Domestic callers: 800-633-8284
International callers: 858-812-6440
PIN #: 207-20-461

About EXACT Sciences Corporation

EXACT Sciences Corporation is an applied genomics company that has developed proprietary technologies that may be used for the early detection of several common cancers. EXACT Sciences has selected colorectal cancer as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Maynard, Mass. Detailed information on EXACT Sciences can be found on the World Wide Web at www.exactsciences.com.

About Laboratory Corporation of America

The first national clinical laboratory to fully embrace genomic testing, Laboratory Corporation of America -Registered Trademark- Holdings (LabCorp-Registered Trademark-) has been a pioneer in commercializing new diagnostic technologies. As a national laboratory with annual revenues of \$2.2 billion in 2001 and over 19,000 employees, the company offers more than 4,000 clinical tests ranging from routine blood analyses to sophisticated molecular diagnostics. Serving more than 200,000 clients nationwide, LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence. The Center for Molecular Biology and Pathology, in Research Triangle Park, North Carolina, offers state-of-the-art molecular gene-based testing in infectious disease, oncology and genetics. Its National Genetics Institute in Los Angeles is an industry leader in developing novel, highly sensitive polymerase chain reaction (PCR) methods for testing hepatitis C and other blood borne infectious agents. LabCorp's Minneapolis-based ViroMed offers molecular microbial testing using real time PCR platforms, while its Center for Esoteric Testing in Burlington, North Carolina, performs the largest volume of specialty testing in the network. LabCorp's clients

include physicians, state and federal government, managed care organizations, hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other clinical laboratories.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' and LabCorp's control. These risks and uncertainties could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences and LabCorp undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding the risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its Form 10-K for the year ended December 31, 2001 and subsequent Forms 10-Q; for the risks faced by LabCorp, see the disclosure contained in LabCorp's public filings with the Securities and Exchange Commission including, without limitation, its Form 10-K for the year ended December 31, 2001 and subsequent Forms 10-Q.